

Clovis Oncology, Inc.  
Form 8-K  
February 19, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): February 14, 2013**

**Clovis Oncology, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**2525 28<sup>th</sup> Street, Suite 100**

**001-35347**  
**(Commission**

**File Number)**

**90-0475355**  
**(I.R.S. Employer**

**Identification No.)**

**80301**

Edgar Filing: Clovis Oncology, Inc. - Form 8-K

**Boulder, Colorado**  
(Address of principal executive offices) (Zip Code)  
**Registrant's telephone number, including area code: (303) 625-5000**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On February 14, 2013, Dr. John C. Reed informed Clovis Oncology, Inc. (the Company ) that he would resign from the Board of Directors of the Company effective immediately. Dr. Reed's resignation from the Board of Directors did not result from any disagreement with the Company, other directors or members of management, and was due to the time constraints and other obligations imposed by his new job as Head of Roche Pharma Research and Early Development.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CLOVIS ONCOLOGY, INC.**

February 15, 2013

By: /s/ Erle T. Mast  
Name: Erle T. Mast  
Title: Executive Vice President and Chief Financial Officer

- 3 -